EUVIMEDEUVIMED entdecken
Crossref

Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment

Shivakumar, P Dinesha, D Udayakumar

Molecular Diversity · 2024

DOI: 10.1007/s11030-024-10812-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2024. Verfasst von Shivakumar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, National Institute of Technology Karnataka, Surathkal, Mangalore, Karnataka, 575025, India. Hauptthemen laut MEDLINE: Drug Design, Antitubercular Agents, Pyrazines, Microbial Sensitivity Tests. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we present a novel series of (E)-4-((2-(pyrazine-2-carbonyl) hydrazineylidene)methyl)phenyl benzenesulfonate (T1-T8) and 4-((E)-(((Z)-amino(pyrazin-2-yl)methylene)hydrazineylidene)methyl)phenyl benzenesulfonate (T9-T16) derivatives which exert their inhibitory effects on decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) through the formation of hydrogen bonds with the pivotal active site Cys387 residue. Their effectiveness against the M. tuberculosis H37Rv strain was examined and notably, three compounds (namely T4, T7, and T12) exhibited promising antitubercular activity, with a minimum inhibitory concentration (MIC) of 1.56 µg/mL. The target compounds were screened for their antibacterial activity against a range of bacterial strains, encompassing S. aureus, B. subtilis, S. mutans, E. coli, S. typhi, and K. pneumoniae. Additionally, their antifungal efficacy against A. fumigatus and A. niger also was scrutinized. Compounds T6 and T12 demonstrated significant antibacterial activity, while compound T6 exhibited substantial antifungal activity. Importantly, all of these active compounds demonstrated exceedingly low toxicity without any adverse effects on normal cells. To deepen our understanding of these compounds, we have undertaken an in silico analysis encompassing Absorption, Distribution, Metabolism, and Excretion (ADME) considerations. Furthermore, molecular docking analyses against the DprE1 enzyme was conducted and Density-Functional Theory (DFT) studies were employed to elucidate the electronic properties of the compounds, thereby enhancing our understanding of their pharmacological potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignAntitubercular AgentsPyrazinesMicrobial Sensitivity TestsMolecular Docking SimulationStructure-Activity RelationshipMycobacterium tuberculosisBacterial ProteinsTuberculosisAlcohol OxidoreductasesBenzenesulfonates

Stichwörter der Autor:innen

Mycobacterium tuberculosisAntibacterial and antifungal activityCytotoxicityDprE1In silico studiesNoncovalent inhibitorsPyrazine

Substanzen

Antitubercular AgentsPyrazinesDprE1 protein, Mycobacterium tuberculosisbenzenesulfonic acidBacterial ProteinsAlcohol OxidoreductasesBenzenesulfonates

Autor:innen und Institutionen

  • Department of Chemistry, National Institute of Technology Karnataka, Surathkal, Mangalore, Karnataka, 575025, India.
  • Department of Chemistry, National Institute of Technology Karnataka, Surathkal, Mangalore, Karnataka, 575025, India. udayakumar@nitk.edu.in.

Zitieren

APA

Shivakumar, Dinesha, P., & Udayakumar, D. (2024). Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment. Molecular Diversity. https://doi.org/10.1007/s11030-024-10812-0

Vancouver

Shivakumar, Dinesha P, Udayakumar D. Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment. Molecular Diversity. 2024. doi:10.1007/s11030-024-10812-0

BibTeX
@article{Shivakumar2024,
  author = {Shivakumar and Dinesha, P and Udayakumar, D},
  title = {Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment},
  journal = {Molecular Diversity},
  year = {2024},
  doi = {10.1007/s11030-024-10812-0}
}
Kostenlos starten →